Introduction {#sec1}
============

Idiopathic membranous nephropathy (IMN) is the most common cause of adult nephrotic syndrome. Approximately 25% to 40% of adult primary nephrotic syndrome cases have IMN. Idiopathic membranous nephropathy is also the most common pathologic type of glomerular disease, and IMN has a longer disease course. The prognosis of IMN varies \[[@cit0001]\]. The pathologic features of IMN are a high number of immune complexes deposited in the glomerular basement membrane on the epithelium side.

The exosome has a double layer plasma membrane structure. Its diameter is approximately 30--100 nm, and it carries a rich protein, mRNA and microRNA. Exosomes are released to the extracellular microenvironment by the cells \[[@cit0002], [@cit0003]\]. They can be released from fibroblasts, dendritic cells, tumor cells and other cells; they are widespread in the urine \[[@cit0004]\], peripheral blood, saliva, cerebrospinal fluid, amniotic fluid, ascites and other body fluids \[[@cit0003], [@cit0005]\]. Therefore, we can detect exosomes and their contents from tissue, cells and body fluids to diagnose and clinically treat the disease, especially kidney disease. Miranda *et al.* \[[@cit0006]\] observed exosomes of renal tubular epithelial cells, podocytes, collecting duct cells and leap cells by transmission electron microscopy, which showed that almost all kidney inherent cells could secrete exosomes. In addition, the authors found that the components of exosomes were different in normal physiological conditions and disease conditions even for the same tissue or body fluid \[[@cit0007]\]. Previous studies have shown that the contents of exosomes have a characteristic change in acute kidney injury \[[@cit0008]\], IgA nephropathy \[[@cit0009]\], diabetic nephropathy \[[@cit0010]\], renal tubular acidosis \[[@cit0006]\], polycystic kidney \[[@cit0011]\] and other kidney diseases. The findings suggested that exosomes can be used as specific markers for early disease diagnosis.

Recent studies have shown that circRNAs can be used as biomarkers for the diagnosis and efficacy of a variety of clinical diseases, such as atherosclerosis \[[@cit0012]\], neurological diseases \[[@cit0013]--[@cit0015]\], diabetes \[[@cit0016]\], tumors \[[@cit0017]--[@cit0019]\] and more. In addition, because of the high stability of the circRNAs and the difficulty of degrading them by exonuclease, we can easily obtain circRNA from body fluid \[[@cit0012]\]. Based on the above characteristics, circRNAs show great potential to regulate human disease genes \[[@cit0020]\], making them a current research focus. In 2005, Huang found many exosomes in human serum and discovered that there is a difference in the exo-circRNA between colorectal cancer and normal human serum \[[@cit0021]\]. The authors speculated that circRNAs could be used as a new biomarker for cancer diagnosis. This discovery renewed people's awareness of circRNAs and exosomes because the authors had linked two emerging areas and further demonstrated the importance of circRNA and exosomes in organisms \[[@cit0021]\].

In this study, we evaluated circRNAs of exosomes. We compared the expression of circRNAs in the exosomes of serum and urine in patients with idiopathic membranous nephropathy and normal healthy controls by gene sequencing. Then, we screened out the differential expression of circRNAs and performed further analysis. The rich data from the analysis provide insight into the pathogenesis of IMN and a solution for future diagnosis and treatment.

Material and methods {#sec2}
====================

Patient assessments and classifications {#sec2.1}
---------------------------------------

The study protocols and consent forms were approved by the Second Clinical Medical College (Shenzhen People's Hospital) of Jinan University and adhere to the Helsinki Declaration guidelines on ethical principles for medical research involving human subjects. Written informed consent was obtained from all participants. Ten IMN patients who had never been treated with glucocorticoids or other immunosuppressive drugs were recruited for this study. In addition, we chose 10 healthy subjects as controls ([Table I](#t0001){ref-type="table"}).

###### 

Clinical characteristics of IMN patients and normal controls

  Group                         IMN group      NC group
  ----------------------------- -------------- --------------
  Age \[years\]                 38.61 ±11.21   35.14 ±12.13
  Sex (M/F)                     7/3            7/3
  Serum creatinine \[µmol/l\]   74.9 ±23.6     63.8 ±20.4
  Proteinuria \[g/24 h\]        2.50 ±1.28     0.08 ±0.03
  Serum albumin \[g/l\]         34.04 ±8.79    42.57 ±3.16
  PLA2R (%)                     60% (6/10)     0% (0/10)

NC group -- normal control group.

Inclusion and exclusion criteria {#sec2.2}
--------------------------------

The inclusion criteria were as follows: IMN patients were hospitalized at Shenzhen People's Hospital nephrology department from November 2015 to October 2016. Renal biopsy confirmed that their pathological type was idiopathic membranous nephropathy and their kidney function was normal before and after admission.

The exclusion criteria were as follows: 1) patients with abnormal renal function based on increased urea nitrogen or creatinine; 2) secondary nephrotic syndrome patients, such as those with hypertensive nephropathy, diabetic nephropathy, lupus nephritis, and hepatitis-related nephritis; and 3) renal pathology results confirming membranous nephropathy, but the patient has co-occurrence of another disease that can cause renal damage, such as hypertension, diabetes, systemic lupus erythematosus, hepatitis B and others.

Collection of serum and urine specimens:

1.  All patients met the inclusion criteria and they were prohibited from eating or drinking the night before specimens were collected.

2.  Venous blood was collected the next morning from elbow vein blood and then kept at 37°C to promote coagulation.

3.  Samples were centrifuged for approximately 10 min at 3000 rpm.

4.  Approximately 2--3 ml of the upper layer of liquid was absorbed into the EP tube, which was marked with identification information (date, number, etc.) and then stored at --80°C.

5.  At the same time, the patient's first morning urine (approximately 100 ml) was collected into a centrifuge tube, which was marked with identifying information (date, number, etc.) and then stored at --80°C.

Exosome isolation {#sec2.3}
-----------------

Exosomes were isolated by the polymer formulation method \[[@cit0022]\] from blood serum using an ExoQuick reagent precipitation kit (System Biosciences, SBI, Mountain View, CA) according to the manufacturer's protocol. This exosome isolation method has been well validated with other techniques, including electron microscopy \[[@cit0022], [@cit0023]\]. All exosomes were stored at --80°C immediately after isolation until further analysis. The total protein concentration of the isolated exosomes was determined using the standard Bradford protein assay (Bio-Rad, Richmond, VA, USA).

Isolation of RNA from exosomes {#sec2.4}
------------------------------

Exosome supernatants were added to 40 pM synthetic cel-miR-39 (UCACCGGGUGUAAAUCAGCUUG) to control and normalize the efficiency of RNA extraction; then, they were transferred to RNase-free tubes for RNA isolation using an miRNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. The RNA sample was washed twice in 500 µl of RPE buffer and eluted in RNase-free water. The isolated RNA was measured using a NanoDrop 1000 ultraviolet spectrophotometer (Thermo Fisher Scientific) and analyzed by reverse transcription polymerase chain reaction (RT-PCR) followed by quantitative PCR (qPCR).

Serum and urine exosome circRNA sequencing {#sec2.5}
------------------------------------------

The total RNA was extracted and then was digested with DNase I to remove rRNA; then, RNase R was used to remove the linear RNA, enriching the circRNAs. The circRNAs were fragmented, and the first strand cDNA was synthesized by reverse transcription using random primers. Then, the second strand cDNA was synthesized using dNTP containing dUTP. The secondary chain product was subjected to terminal repair, and was pulsed "A" and a linker. The reaction mixture was digested with USER enzyme to remove the second strand cDNA containing dUTP, and a primer was added to amplify via PCR and obtain a chain-specific cDNA library. The fragments were screened by magnetic beads. Quality control was performed and fragments were further sequenced on a machine. The experimental procedure is summarized in [Figure 1](#f0001){ref-type="fig"}.

![The main experimental process of circular RNA gene sequencing. QC1: detection of the total RNA concentration, purity, completeness; QC2: confirmed that more than 99% of the rRNA had been removed; QC3: confirmed that RNA was fragmented into approximately 200-bp fragments; QC4: detected the fragment concentration and size and library concentration. The distribution of the significantly differentially expressed miRNA of cells in the cellular component with high throughput sequencing](AMS-15-36465-g001){#f0001}

Bioinformatics analysis {#sec2.6}
-----------------------

The expression values calculated for the differential proteins and peptides were used for the distance and average to determine the linkage for gene ontology (GO) analysis. In pathway analysis, interactions between genes in the range of genomes were analyzed by downloading the pathway data in KEGG. Finally, the results of the above data were merged into a comprehensive gene inter-relationship network. The established gene network could directly reflect the inter-relationships between genes at a whole-cell level as well as the stability of the gene regulatory network.

Statistical analysis {#sec2.7}
--------------------

The back-spliced junction reads and linear mapped reads were combined and scaled to reads per million mapped reads (RPM) to quantify circRNA expression levels. Differences in circRNA expression levels were analyzed using Student's *t*-test. *P* \< 0.05 was considered statistically significant.

Results {#sec3}
=======

Total RNA quality and concentration determination results {#sec3.1}
---------------------------------------------------------

RNA was extracted and purified using an RNA isolation kit. The total RNA of the IMN and NC groups was detected with a Qubit3.0 fluorescence meter. The results are shown in [Tables II](#t0002){ref-type="table"} and [III](#t0003){ref-type="table"}. In the tables, the total amount of exosome RNA measured in each group was more than 200 ng, and the obtained circRNAs had high purity and good integrity, and could be used for later experiments.

###### 

Concentration of exosome total RNA

  Sample name   Serum volume \[ml\]   Exosome RNA concentration \[ng/µl\]   Exosome RNA total amount \[ng\]
  ------------- --------------------- ------------------------------------- ---------------------------------
  IMN group     28.7                  9.69                                  242.30
  NC group      23                    33.40                                 400.80

IMN group -- IMN group, NC group -- normal control group.

###### 

Concentration of exosome total RNA

  Sample name   Urine volume \[ml\]   Exosome RNA concentration \[ng/µl\]   Exosome RNA total amount \[ng\]
  ------------- --------------------- ------------------------------------- ---------------------------------
  IMN group     980                   16.50                                 445.50
  NC group      970                   16.70                                 367.40

IMN group -- IMN group, NC group -- normal control group.

Types of circRNAs {#sec3.2}
-----------------

Compared with the healthy control group, the types of circRNAs in the serum of the patients with idiopathic membranous nephropathy decreased and mainly appeared as intron region sources. However, the circRNAs in the urinary exosomes increased, and mainly appeared to have an exon region source ([Table IV](#t0004){ref-type="table"}).

###### 

Species of exosome circRNA

  Variable                                        IMN serum   IMN urine   NC serum   NC urine
  ----------------------------------------------- ----------- ----------- ---------- ----------
  Total number of circRNAs                        85          286         227        12
  Number of circRNAs from the circBase database   0           198         6          1
  Number of circRNAs from the exon region         5           218         12         2
  Number of circRNAs from the intron region       60          58          189        6
  Number of circRNAs from the intergenic region   20          10          26         1

IMN group -- IMN group, NC group -- normal control group.

Difference analysis of circRNAs {#sec3.3}
-------------------------------

According to the expression level of circRNAs, when the difference multiple (ratio) was more than 2 or less than 0.5 and FDR ≤ 0.001, the circRNAs were considered differentiated. In this study, the log2 ratio was used instead of multiple differences. The filter criteria of significantly differentially expressed genes were FDR ≤ 0.001 and \|log2 ratio\| ≥ 1.

### Differential expression of circRNAs in serum and urine exosomes of IMN patients {#s3c1}

According to the experimental results, there were 59 species of circRNA with significantly different expression compared to serum and urine exosomes in IMN patients; 32 species were up-regulated ([Table V](#t0005){ref-type="table"}) and 27 species were down-regulated ([Table VI](#t0006){ref-type="table"}). Most of these circRNAs had an intron source. The corresponding genes were mainly SNORA25, SNORA31, SNORA51, SNORA75 and other nucleolus small RNAs. The log2 ratio of chrY: 13688616\|13833086 was 27.592 in the up-regulation circRNA, which was the most significant. The log2 ratio of chrY:13842647\|13855594 was --26.379 in the down-regulation circRNA, which was the most significant. However, the two most significantly different circRNAs in the circBase gene pool had no corresponding gene, suggesting that they may be newly discovered genes.

###### 

Up-regulated circRNAs between the IMN serum and IMN urine

  circRNA                      Log2 ratio   Up/down   CircRNA type        Chromosome localization   Gene localization
  ---------------------------- ------------ --------- ------------------- ------------------------- -------------------
  chrY:13688616\|13833086      27.592       Up        Intergenic region   chrY                      n/a
  chrY:13650802\|13725921      26.677       Up        Intergenic region   chrY                      n/a
  chrY:13844080\|13851741      25.449       Up        Intergenic region   chrY                      n/a
  chr3:114874721\|114874739    24.936       Up        Intron              chr3                      SNORA25
  chr4:49133318\|49151812      24.363       Up        Intron              chr4                      SNORA75
  chr4:49133318\|49151817      23.766       Up        Intron              chr4                      SNORA75
  chr1:246981249\|246981308    23.51        Up        Intron              chr1                      SNORA25
  chr6:39390231\|39390251      23.444       Up        Intron              chr6                      KIF6
  chrY:13688616\|13810318      23.251       Up        Intergenic region   chrY                      n/a
  chrY:13867301\|13869486      23.116       Up        Intergenic region   chrY                      n/a
  chr3:42154842\|42154889      23.059       Up        Intron              chr3                      TRAK1
  chr8:70602312\|70602409      22.531       Up        Intron              chr8                      SLCO5A1
  chr4:49118019\|49128722      22.398       Up        Intron              chr4                      SNORA51
  chr10:39103465\|39105726     22.302       Up        Intron              chr10                     SNORA31
  chr8:70602353\|70602431      22.029       Up        Intron              chr8                      SLCO5A1
  chr8:70602360\|70602427      21.967       Up        Intron              chr8                      SLCO5A1
  chr10:39085864\|39088295     21.903       Up        Intron              chr10                     SNORA31
  chr1:91853081\|91853139      21.766       Up        Intron              chr1                      SNORA31
  chrY:13684026\|13844079      21.614       Up        Intergenic region   chrY                      n/a
  chr3:114874721\|114874743    21.614       Up        Intron              chr3                      SNORA25
  chr8:70602355\|70602427      21.531       Up        Intron              chr8                      SLCO5A1
  chr4:49637530\|49641867      21.351       Up        Intron              chr4                      SNORA51
  chr4:49120156\|49121084      21.351       Up        Intron              chr4                      SNORA51
  chr8:70602312\|70602382      21.351       Up        Intron              chr8                      SLCO5A1
  chr17:22246001\|22253301     21.351       Up        Intron              chr17                     snoU13
  chr21:10778969\|10808326     21.251       Up        Intron              chr21                     SNORA70
  chr1:108113527\|108113595    21.251       Up        Intron              chr1                      SNORA31
  chrY:13659053\|13844079      21.144       Up        Intron              chrY                      n/a
  chr15:101250552\|101250653   21.144       Up        Intron              chr15                     snoU13
  chr21:44593818\|44593903     21.144       Up        Intergenic region   chr21                     n/a
  chr7:100550808\|100551062    4.267        Up        Exon                chr7                      MUC3A
  chrY:13805036\|13841134      3.876        Up        Intergenic region   chrY                      n/a

NB: Gene ID n/a indicates that there was no matched circRNA in the circBase gene bank.

###### 

Down-regulated circRNAs between the IMN serum and IMN urine

  circRNA                     Log2 ratio   Up/down   CircRNA type        Chromosome localization   Gene localization
  --------------------------- ------------ --------- ------------------- ------------------------- -------------------
  chrY:13842647\|13855594     --26.379     Down      Intergenic region   chrY                      n/a
  chrY:13650802\|13659298     --26.116     Down      Intergenic region   chrY                      n/a
  chr17:22248380\|22253301    --25.516     Down      Intron              chr17                     snoU13
  chr8:43092760\|43093139     --25.146     Down      Intron              chr8                      SNORD112
  chr8:43092873\|43096758     --24.588     Down      Intron              chr8                      SNORD112
  chr4:90986390\|90986415     --24.441     Down      Intron              chr4                      SNORA51
  chr4:49103783\|49111822     --23.791     Down      Intron              chr4                      SNORA51
  chr10:39139428\|39147131    --23.244     Down      Intron              chr10                     SNORA31
  chr4:49641376\|49652154     --23.221     Down      Intron              chr4                      SNORA51
  chr18:54265993\|54266355    --23.079     Down      Exon                chr18                     TXNL1
  chr6:158779108\|158779264   --22.894     Down      Intron              chr6                      TULP4
  chr2:19441309\|19442090     --22.806     Down      Intron              chr2                      SNORA51
  chr3:96221435\|96221837     --22.776     Down      Intron              chr3                      SNORA25
  chrY:13801063\|13849765     --22.266     Down      Intergenic region   chrY                      n/a
  chr8:43095798\|43096720     --21.976     Down      Intron              chr8                      SNORD112
  chr6:61899754\|61913064     --21.806     Down      Intron              chr6                      SNORD45
  chr8:43093689\|43097076     --21.681     Down      Intron              chr8                      SNORD112
  chr2:233244474\|233272478   --21.614     Down      Intron              chr2                      snoU13
  chr2:221311242\|221311332   --21.543     Down      Intron              chr2                      SNORA75
  chr20:30954187\|30956926    --21.543     Down      Exon                chr20                     ASXL1
  chr4:35172567\|35172590     --21.469     Down      Intron              chr4                      SNORA75
  chr6:2024936\|2340390       --21.391     Down      Intron              chr6                      snoU13
  chr10:18831781\|18831900    --21.309     Down      Intron              chr10                     SNORA31
  chr10:42400571\|42533897    --21.221     Down      Intron              chr10                     SNORA31
  chr15:30465080\|30465505    --21.128     Down      Intron              chr15                     SNORA48
  chr19:34882415\|34883413    --3.063      Down      Intron              chr19                     GPI
  chrY:13691698\|13851741     --1.454      Down      Intergenic region   chrY                      n/a

NB: Gene ID n/a indicates that there was no matched circRNA in the circBase gene bank.

### Differential expression of circRNAs in serum exosomes of IMN and NC patients {#s3c2}

According to the experimental results, there were 89 species of circRNAs with significantly different expression compared to IMN patients' serum exosomes and NC patients' serum exosomes; 49 species were up-regulated ([Table VII](#t0007){ref-type="table"}) and 40 species were down-regulated ([Table VIII](#t0008){ref-type="table"}). Most of these circRNAs had an intron source. The corresponding genes were mainly SNORA25, SNORA51, SNORA31, SNORA75, SNORD112 and other nucleolus small RNAs. The log2 ratio of chrY:13688616\|13833086 was 27.592 in the up-regulation circRNAs, which was the most significant. However, the circRNAs in the circBase gene pool had no corresponding gene, which suggested that it may be a newly discovered gene. The log2 ratio of chr2:233244474\|233272478 was --27.111 in the down-regulation circRNAs, which was the most significant, and the corresponding gene is the snoU13 gene. This gene is mainly expressed nucleolus small RNA and plays a role in RNA treatment and modification.

###### 

Up-regulated circRNAs between the IMN and NC groups in serum

  circRNA                      Log2 ratio   Up/down   CircRNA type        Chromosome localization   Gene localization
  ---------------------------- ------------ --------- ------------------- ------------------------- -------------------
  chrY:13688616\|13833086      27.592       Up        Intergenic region   chrY                      n/a
  chrY:13650802\|13725921      26.677       Up        Intergenic region   chrY                      n/a
  chr3:114874721\|114874739    24.936       Up        Intron              chr3                      SNORA25
  chr4:49133318\|49151812      24.363       Up        Intron              chr4                      SNORA51
  chr4:49133318\|49151817      23.766       Up        Intron              chr4                      SNORA51
  chr6:39390231\|39390251      23.444       Up        Intron              chr6                      KIF6
  chrY:13688616\|13810318      23.251       Up        Intergenic region   chrY                      n/a
  chr3:42154842\|42154889      23.059       Up        Intron              chr4                      TRAK1
  chr4:49118019\|49128722      22.398       Up        Intron              chr4                      SNORA51
  chr10:39103465\|39105726     22.302       Up        Intron              chr10                     SNORA31
  chr10:39085864\|39088295     21.903       Up        Intron              chr10                     SNORA31
  chr1:91853081\|91853139      21.766       Up        Intron              chr1                      HFM1
  chrY:13684026\|13844079      21.614       Up        Intergenic region   chrY                      n/a
  chr3:114874721\|114874743    21.614       Up        Intron              chr3                      SNORA25
  chr8:70602355\|70602427      21.531       Up        Intron              chr8                      SLCO5A1
  chr4:49637530\|49641867      21.351       Up        Intron              chr4                      SNORA51
  chr4:49120156\|49121084      21.351       Up        Intron              chr4                      SNORA51
  chr17:22246001\|22253301     21.351       Up        Intron              chr17                     snoU13
  chr21:10778969\|10808326     21.251       Up        Intron              chr21                     SNORA70
  chr1:108113527\|108113595    21.251       Up        Intron              chr1                      SNORA51
  chrY:13659053\|13844079      21.144       Up        Intergenic region   chrY                      n/a
  chr15:101250552\|101250653   21.144       Up        Intron              chr15                     snoU13
  chr21:44593818\|44593903     21.144       Up        Intergenic region   chr21                     n/a
  chr2:5845511\|5845954        20.766       Up        Intron              chr2                      snoU13
  chr4:70296654\|70296710      20.614       Up        Intron              chr4                      SNORA51
  chr7:71387989\|71388027      20.614       Up        Intron              chr7                      CALN1
  chr16:47538682\|47538754     20.614       Up        Intron              chr16                     PHKB
  chr19:34882415\|34883413     20.444       Up        Intron              chr19                     GPI
  chr2:92305623\|92309358      20.444       Up        Intron              chr2                      SNORA75
  chr20:59906635\|59906776     20.251       Up        Intron              chr20                     CDH4
  chr1:91852914\|91852996      20.029       Up        Intron              chr1                      HFM1
  chr10:38778641\|38816581     20.029       Up        Intron              chr10                     SNORA31
  chrX:108297654\|108297709    20.029       Up        Exon                chrX                      CTD-2328D6.1
  chr12:38237430\|38502951     20.029       Up        Intron              chr12                     SNORD112
  chr20:59906715\|59906776     19.766       Up        Intron              chr20                     CDH4
  chr14:70396886\|70396954     19.766       Up        Intron              chr14                     SMOC1
  chr8:70602368\|70602431      19.766       Up        Intron              chr8                      SLCO5A1
  chr10:51358680\|51636067     19.766       Up        Intron              chr10                     SNORA31
  chr8:70602312\|70602420      19.766       Up        Intron              chr8                      SLCO5A1
  chr8:70602360\|70602427      4.413        Up        Intron              chr8                      SLCO5A1
  chr1:246981249\|246981308    3.955        Up        Intron              chr1                      SNORA25
  chr7:100550808\|100551062    3.349        Up        Exon                chr7                      MUC3A
  chrY:13867301\|13869486      2.807        Up        Intergenic region   chrY                      n/a
  chrY:13805036\|13841134      2.806        Up        Intergenic region   chrY                      n/a
  chr8:70602353\|70602431      2.567        Up        Intron              chr8                      SLCO5A1
  chrY:13691698\|13851741      2.522        Up        Intergenic region   chrY                      n/a
  chr8:70602312\|70602409      2.276        Up        Intron              chr8                      SLCO5A1
  chrY:13844080\|13851741      2.012        Up        Intergenic region   chrY                      n/a
  chrY:13688616\|13851691      1.936        Up        Intergenic region   chrY                      n/a

NB: Gene ID n/a indicates that there was no matched circRNA in the circBase gene bank.

###### 

Down-regulated circRNA between the IMN and NC groups in serum

  circRNA                     Log2 ratio   Up/down   CircRNA type        Chromosome localization   Gene localization
  --------------------------- ------------ --------- ------------------- ------------------------- -------------------
  chr2:233244474\|233272478   --27.111     Down      Intron              chr2                      snoU13
  chr17:39537965\|39552828    --26.966     Down      Intron              chr17                     SCARNA20
  chr22:42910112\|42970824    --26.895     Down      Intron              chr22                     Y_RNA
  chr6:31122297\|31122344     --26.054     Down      Exon                chr6                      CCHCR1
  chr12:52863454\|52909616    --25.798     Down      Intron              chr12                     SNORD112
  chr19:36066505\|36066634    --25.772     Down      Intron              chr19                     SNORA70
  chr4:1005136\|1242947       --25.454     Down      Intergenic region   chr4                      n/a
  chr4:159973545\|159973572   --25.028     Down      Intron              chr4                      SNORA51
  chrY:13842647\|13855594     --24.668     Down      Intergenic region   chrY                      n/a
  chr21:37558665\|37558690    --22.588     Down      Intron              chr21                     DOPEY2
  chr15:31645251\|31645272    --22.461     Down      Intron              chr15                     KLF13
  chr10:39139428\|39141998    --22.387     Down      Intron              chr10                     SNORA31
  chr17:39938846\|39938869    --22.336     Down      Intron              chr17                     JUP
  chr17:22253135\|22260437    --22.198     Down      Intron              chr17                     snoU13
  chr17:79502678\|79502749    --21.981     Down      Intron              chr17                     FSCN2
  chr17:48266264\|48272839    --21.912     Down      Exon                chr17                     COL1A1
  chr10:38804894\|38818467    --21.894     Down      Intron              chr10                     SNORA31
  chr1:74953936\|74953971     --21.858     Down      Intron              chr1                      TMEM56
  chr5:116075463\|116075487   --21.764     Down      Intron              chr5                      SNORA70
  chr18:18518121\|18519655    --21.764     Down      Intron              chr18                     SNORD112
  chr7:148028455\|148028529   --21.744     Down      Intron              chr7                      CNTNAP2
  chr2:189121958\|189121979   --21.724     Down      Intron              chr2                      SNORA48
  chrX:3349826\|3349848       --21.642     Down      Intron              chrX                      snoU13
  chr11:75979847\|75979884    --21.599     Down      Intron              chr11                     SNORA1
  chr15:42134880\|42134903    --21.509     Down      Exon                chr15                     PLA2G4B
  chr18:32291302\|32291329    --21.387     Down      Intron              chr18                     DTNA
  chr13:36337738\|36337787    --21.362     Down      Intron              chr13                     SNORA25
  chr17:31559413\|31559527    --21.336     Down      Intron              chr17                     ASIC2
  chr9:19592476\|19592555     --21.282     Down      Intron              chr9                      SLC24A2
  chr7:76626497\|76626556     --21.282     Down      Intron              chr7                      DTX2P1
  chr8:124924619\|124924638   --21.198     Down      Intron              chr8                      FER1L6
  chr1:7769121\|7769144       --21.078     Down      Intron              chr1                      CAMTA1
  chr14:37211610\|37211628    --21.046     Down      Intron              chr14                     SLC25A21
  chr1:32294226\|32294254     --20.947     Down      Intron              chr1                      SNORA70
  chr17:31559408\|31559527    --20.912     Down      Intron              chr17                     ASIC2
  chr19:56438931\|56438947    --20.84      Down      Intron              chr19                     NLRP13
  chr1:155048684\|155048737   --20.764     Down      Intron              chr1                      EFNA3
  chr20:46681136\|46681159    --20.764     Down      Intron              chr20                     snoU13
  chr1:233454768\|233454781   --20.764     Down      Intron              chr1                      SNORA25
  chr6:104238460\|104238484   --3.592      Down      Intron              chr6                      SNORA33

NB: Gene ID n/a indicates that there was no matched circRNA in the circBase gene bank.

### Differential expression of circRNAs in urine exosomes of IMN and NC patients {#s3c3}

According to the experimental results, there were 60 species of circRNAs with significantly different expression compared to IMN patients' urine exosomes and NC patients' urine exosomes; 54 species were up-regulated ([Table IX](#t0009){ref-type="table"}) and 6 species were down-regulated ([Table X](#t0010){ref-type="table"}). Approximately 55% were intron sources, 30% were exon sources and 15% were intergenic regions. The corresponding genes were mainly SNORA51, SNORA31, SNORA70, SNORA75, SNORD112 and other nucleolus small RNAs. The log2 ratio of chrY:13842647\|13855594 was 26.379 in the up-regulated circRNA, which was the most significant. The log2 ratio of chrY:13688616\|13833086 was --25.049 in the down-regulated circRNAs, which was the most significant. However, the two most significantly different circRNAs in the circBase gene pool had no corresponding gene, suggesting that they may be newly discovered genes.

###### 

Up-regulated circRNAs between the IMN and NC groups in urine

  circRNA                     Log2 ratio   Up/down   CircRNA type        Chromosome localization   Gene localization
  --------------------------- ------------ --------- ------------------- ------------------------- -------------------
  chrY:13842647\|13855594     26.379       Up        Intergenic region   chrY                      n/a
  chrY:13691698\|13851741     26.006       Up        Intergenic region   chrY                      n/a
  chr17:22248380\|22253301    25.516       Up        Intron              chr17                     snoU13
  chr8:43092760\|43093139     25.146       Up        Intron              chr8                      SNORD112
  chr8:43092873\|43096758     24.588       Up        Intron              chr8                      SNORD112
  chr4:49103783\|49111822     23.791       Up        Intron              chr4                      SNORA51
  chr19:34882415\|34883413    23.507       Up        Intron              chr19                     GPI
  chr10:39139428\|39147131    23.244       Up        Intron              chr10                     SNORA31
  chr4:49641376\|49652154     23.221       Up        Intron              chr4                      SNORA51
  chr18:54265993\|54266355    23.079       Up        Exon                chr18                     TXNL1
  chr6:158779108\|158779264   22.894       Up        Intron              chr6                      TULP4
  chr2:19441309\|19442090     22.806       Up        Intron              chr2                      SNORA51
  chr3:96221435\|96221837     22.776       Up        Intron              chr3                      SNORA25
  chrY:13801063\|13849765     22.266       Up        Intergenic region   chrY                      n/a
  chr8:43095798\|43096720     21.976       Up        Intron              chr8                      SNORD112
  chr6:61899754\|61913064     21.806       Up        Intron              chr6                      SNORD45
  chr8:43093689\|43097076     21.681       Up        Intron              chr8                      SNORD112
  chr2:233244474\|233272478   21.614       Up        Intron              chr2                      snoU13
  chr2:221311242\|221311332   21.543       Up        Intron              chr2                      SNORA75
  chr20:30954187\|30956926    21.543       Up        Exon                chr20                     ASXL1
  chr4:35172567\|35172590     21.469       Up        Intron              chr4                      SNORA75
  chr6:2024936\|2340390       21.391       Up        Intron              chr6                      snoU13
  chr10:18831781\|18831900    21.309       Up        Intron              chr10                     SNORA31
  chr10:42400571\|42533897    21.221       Up        Intron              chr10                     SNORA31
  chr15:30465080\|30465505    21.128       Up        Intron              chr15                     SNORA48
  chr21:10788458\|10853762    21.029       Up        Intron              chr21                     SNORA70
  chr18:18518121\|18519655    20.806       Up        Intron              chr18                     SNORD112
  chrY:13805036\|13841134     20.806       Up        Intergenic region   chrY                      n/a
  chr3:196118684\|196129890   20.681       Up        Exon                chr3                      UBXN7
  chr5:137320946\|137324004   20.543       Up        Exon                chr5                      FAM13B
  chr9:137976113\|137976207   20.543       Up        Intron              chr9                      OLFM1
  chr4:49101961\|49155306     20.543       Up        Intron              chr4                      SNORA75
  chr11:33307959\|33309057    20.391       Up        Exon                chr11                     HIPK3
  chr17:20107646\|20109225    20.221       Up        Exon                chr17                     SPECC1
  chr19:7034465\|7036161      20.221       Up        Intron              chr19                     Y_RNA
  chr8:141874411\|141900868   20.029       Up        Exon                chr8                      PTK2
  chr8:99718695\|99719539     20.029       Up        Exon                chr8                      STK3
  chr13:64330137\|64398060    20.029       Up        Intron              chr13                     SNORA25
  chr8:43093228\|43097076     20.029       Up        Intron              chr8                      SNORD112
  chrY:13140123\|13456953     20.029       Up        Intergenic region   chrY                      n/a
  chr21:16386665\|16415895    19.806       Up        Exon                chr21                     NRIP1
  chr10:32197100\|32199491    19.806       Up        Exon                chr10                     ARHGAP12
  chr14:76633006\|76662315    19.806       Up        Exon                chr14                     GPATCH2L
  chrY:13137990\|13450019     19.806       Up        Intergenic region   chrY                      n/a
  chr21:10789780\|10836717    19.543       Up        Intron              chr21                     SNORA70
  chr2:61749746\|61761038     19.543       Up        Exon                chr2                      XPO1
  chr5:72370569\|72373320     19.543       Up        Exon                chr5                      FCHO2
  chr1:180953813\|180962561   19.543       Up        Exon                chr1                      STX6
  chr2:228252617\|228252643   19.543       Up        Intron              chr2                      SNORA75
  chr2:202010101\|202014558   19.543       Up        Exon                chr2                      CFLAR
  chr20:52773708\|52788209    19.543       Up        Exon                chr20                     CYP24A1
  chr9:113734353\|113735838   19.543       Up        Exon                chr9                      LPAR1
  chr6:4891947\|4892613       4.346        Up        Exon                chr6                      CDYL
  chrY:13650802\|13659298     1.893        Up        Intergenic region   chrY                      n/a

NB: Gene ID n/a indicates that there was no matched circRNA in the circBase gene bank.

###### 

Down-regulated circRNAs between the IMN and NC groups in urine

  circRNA                      Log2 ratio   Up/down   CircRNA type        Chromosome localization   Gene localization
  ---------------------------- ------------ --------- ------------------- ------------------------- -------------------
  chrY:13688616\|13833086      --25.049     Down      Intergenic region   chrY                      n/a
  chr17:25267933\|25267961     --23.323     Down      Intron              chr17                     snoU13
  chr10:39084961\|39105726     --23.142     Down      Intron              chr10                     SNORA31
  chr10:38787997\|39138199     --22.485     Down      Intron              chr10                     SNORA31
  chr14:105944010\|105944069   --20.583     Down      Intron              chr14                     CRIP2
  chrY:13688616\|13851691      --1.126      Down      Intergenic region   chrY                      n/a

NB: Gene ID n/a indicates that there was no matched circRNA in the circBase gene bank.

Bioinformatics analysis {#sec3.4}
-----------------------

Target genes were analyzed for their potential functions using GO and KEGG pathways. GO analysis demonstrated that the target genes were associated with cellular processes, multicellular organisms, pigmentation, the development process and the response to stimuli at both serum and urine exosomes ([Figures 2](#f0002){ref-type="fig"} and [3](#f0003){ref-type="fig"}). Furthermore, significantly associated pathways comprising the target genes were obtained for the assessed circRNAs. Interestingly, we selected 29 metabolic pathways in the serum sample; of all 29 pathways, 21 had PLA abnormalities, and the corresponding gene was PLA2G4B. The top 20 signaling pathways are shown in [Figure 4](#f0004){ref-type="fig"}, while the platelet activation signaling pathway was the most widely distributed ([Figure 5](#f0005){ref-type="fig"}). In addition, we selected 35 metabolic pathways in the urine samples. The top 20 are shown in [Figure 6](#f0006){ref-type="fig"}, while the P13K-Akt signaling pathway was the most widely distributed ([Figure 7](#f0007){ref-type="fig"}).

![GO annotation of differentially expressed circRNAs in the serum exosomes of IMN patients compared to the control group. GO annotation consisted of the biological process, cellular components, and molecular function](AMS-15-36465-g002){#f0002}

![GO annotation of differentially expressed circRNAs in urine exosomes of IMN patients compared to the control group. GO annotation consisted of the biological process, cellular component, and molecular function](AMS-15-36465-g003){#f0003}

![KEGG pathway analysis of predicted targets for differentially expressed circRNAs in serum exosomes of IMN patients compared to the control group. The bluer the circle, the more significant the pathway enrichment. The bigger the circle, the higher the number of pathway genes](AMS-15-36465-g004){#f0004}

![Pathway analysis of differential genes: platelet activation. Red marks indicate the genes with differential profiles](AMS-15-36465-g005){#f0005}

![KEGG pathway analysis of predicted targets for differentially expressed circRNAs in urine exosomes of IMN patients compared to the control group. The bluer the circle, the more significant the pathway enrichment. The bigger the circle, the higher the number of pathway genes](AMS-15-36465-g006){#f0006}

![Pathway analysis of differential genes: the PI3K-Akt signaling pathway. Red marks indicate the genes with differential profiles](AMS-15-36465-g007){#f0007}

Discussion {#sec4}
==========

Beck *et al.* \[[@cit0024]\] detected anti-PLA2R antibodies for the first time in IMN patient plasma samples. Substantial clinical data showed its specificity of up to 100% and sensitivity of approximately 70% to 80%, which indicated that they can be used as IMN-specific diagnostic markers.

The latest study \[[@cit0024], [@cit0025]\] showed that the mannose-binding lectin pathway was the major complement activation in the pathogenesis of IMN. In this study, the mucin 3A (MUC3A) gene, corresponding to the circRNAs of chromosome 7 encoding chr7: 100550808\|100551062 in the serum exosomes of IMN patients, was significantly up-regulated. It was also found that MUC3A was encoded by an exon-derived gene. Existing studies have shown that \[[@cit0026]\] MUC3A is a mucin cluster located on the 7p22 chromosome. Additionally, MUC3A belongs to a transmembrane glycoprotein. Authors \[[@cit0027]\] found that 71% of the amino acid repeated sequences encoded by MUC3 were serine/threonine and 6% proline. Studies have demonstrated that the activation of serine proteases is achieved by a change in specific amino acid residues in the center of serine-dominated activity \[[@cit0028]\]. Because most of the amino acids encoded by the MUC3A gene in this study were serine/threonine, we speculate that the MUC3A gene may encode the relevant amino acids and then play an important role in the pathogenesis of IMN through the mannose-binding lectin pathway. Previous evidence suggests that PLA2R-IgG4 can play a role by activating the complement lectin pathway with MBL \[[@cit0029]\]. The serine of the MUC3A gene also plays a role in the lectin binding pathway. Therefore, we further speculated that the MUC3A gene may be associated with IgG4 and anti-PLA2R antibody expression. There were some relationships in the diagnosis and prognosis of IMN. In addition, it was reported \[[@cit0030]\] that MUC3A is a class of membrane-associated mucins, which can mediate some of the particles and related pathogens adhering to the mucosal surface. Additionally, MUC3A is involved in binding of the receptor and ligand and signal transduction pathways. MUC3A can mediate the adhesion of the relevant particles to the membrane surface and participate in the receptor ligand binding process, suggesting that MUC3A may also play a role in the formation of immune complexes.

In addition, in this experiment, the genes for which we observed a significant difference in the circRNAs are mainly intron-derived circRNAs. The corresponding genes are SNORA25, SNORA31, SNORA70, SNORA75, SNORD112 and other small nucleolar RNAs (snoRNAs). An increasing number of studies have shown that snoRNAs can be further processed to form shorter RNA fragments, and these short fragments of snoRNAs have microRNA-like functions. This finding suggested that snoRNAs may act as microRNA precursors \[[@cit0031]\]. One study \[[@cit0032], [@cit0033]\] showed that circRNAs of different gene sources exist in different parts of the cell and the function is also different. The corresponding genes of circRNAs that we obtained in this experiment were mainly the intron source for coding snoRNAs. Therefore, we speculate that in the pathogenesis of IMN at the gene level, the circRNAs of the intron source may code snoRNAs that modify the mRNA during and before transcription as well as regulating the gene expression at the mRNA level.

Studies have shown that alleles-PLA2R1 and HLA-DQA1 are closely related to IMN \[[@cit0034]\]. In this study, we selected 29 metabolic pathways in the serum sample; 21 had PLA abnormalities. IMN does not appear to occur through a specific signaling pathway; instead, several pathways appear to work at the same time. Additionally, the corresponding gene of PLA was PLA2G4B, which corresponds to PLA2R positivity in IMN patients. IMN may be associated with the PLA2G4B gene. Therefore, evaluation of PLA2G4B may provide new clues for the diagnosis and treatment of IMN.

In conclusion, we found that there were abnormal expression levels of circRNAs in serum and urine exosomes in IMN patients. These circRNAs with abnormal expression could be involved in IMN pathogenesis. However, the specific mechanism and function of the circRNAs with differential expression in the disease require more direct evidence. However, with the continuous development of biological technology and continuous research on circRNAs, circRNAs will eventually provide a new theoretical basis in the disease diagnosis, treatment and prognosis. Additionally, the study of PLA2G4B may provide new clues for the diagnosis and treatment of IMN.
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